IFNB1 and neoplasm: Combining Alb-IFNβ pretreatment with the CRT-E7 vaccine significantly enhanced antigen-specific CD8+ T cell immunity, reducing tumor growth and prolonging survival in TC-1 tumor-bearing mice.